"DARATUMUMAB APPEARS to be the "gift that keeps on giving"
76791 Helge Larsen/PI-redaktør 25/3 2019 11:22
"DARATUMUMAB APPEARS to be the "gift that keeps on giving" to the myeloma community. "It seems we can add daratumumab to almost anything and make the regimen better. It's got good activity and a good safety profile," said Kenneth Shain, MD, PhD, Director of the Myeloma Working Group at Moffitt Cancer Center, Tampa, who commented on the benefit observed by adding the monoclonal antibody to doublets and triplets in trials described at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition".
Læs mere
http://www.ascopost.com/issues/march-25-2019/benefit-of-adding-daratumumab-to-initial-therapy-in-multiple-myeloma/
Læs mere
http://www.ascopost.com/issues/march-25-2019/benefit-of-adding-daratumumab-to-initial-therapy-in-multiple-myeloma/
